Detection and chemoradiotherapeutic evaluation of advanced esophageal squamous cell carcinoma using gallium-67 SPET: A preliminary study

Tadaki Nakahara, Takashi Togawa, Matsuo Nagata, Kazunori Kikuchi, Kazuo Hatano, Nobuharu Yui, Atsushi Kubo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

About 20 years ago, gallium-67 planar scintigraphy was introduced for the evaluation of advanced esophageal squamous cell carcinoma (AESCC). Although single-photon emission tomography (SPET) is now available in many institutions, there have been no reports regarding the evaluation of AESCC using 67Ga SPET. The aims of this preliminary study were to assess the potential of 67Ga SPET for the detection of AESCC and to further evaluate whether 67Ga SPET can predict the effect of preoperative chemoradiotherapy on AESCC. Thirty-eight patients with histologically proven AESCC (35 men and 3 women, mean age 62±6.9 years) underwent 67Ga SPET before and after preoperative chemoradiotherapy. The histological response to the chemoradiotherapy was determined from a surgical specimen of the esophagus: grade 0, 100% viable tumor cells; grade 1a, 99%-67%; grade 1b, 66%-34%; grade 2, 33%-1%; grade 3, no viable cells. Thirty-seven out of 38 AESCCs (97.4%) were detected on pre-chemoradiotherapy SPET. In these 37 cancers, the tumor-to-lung ratio (TLRpre) was 3.5±2 (range 1.5-9.6). Post-chemoradiotherapy SPET exhibited positive results in 22 cancers, with a TLRpost of 1.8±0.4 (range 1.1-2.6). No patient exhibiting a pathologically complete response had a positive post-chemoradiotherapy SPET result, whereas 80% of patients with negative post-chemoradiotherapy SPET (12/15) results had residual tumor. The percent reduction rate was defined as (TLRpre-TLRpost)/TLRpre x100 and did not correlate with histological response grade (P=0.5169 for Kruskal-Wallis test). These results suggest that 67Ga SPET is a powerful tool for the detection of AESCC. However, 67Ga SPET seems to be of little use in predicting the effects of preoperative chemoradiotherapy on AESCC. Further studies are warranted in order to further clarify the clinical usefulness of 67Ga SPET in patients with AESCC.

Original languageEnglish
Pages (from-to)1072-1077
Number of pages6
JournalEuropean Journal Of Nuclear Medicine
Volume29
Issue number8
DOIs
Publication statusPublished - 2002

Fingerprint

Gallium
Photons
Tomography
Chemoradiotherapy
Esophageal Squamous Cell Carcinoma
Neoplasms
Residual Neoplasm
Radionuclide Imaging
Esophagus

Keywords

  • Esophageal cancer
  • Gallium-67
  • Preoperative chemoradiotherapy
  • Single-photon emission tomography
  • Therapeutic effect

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Detection and chemoradiotherapeutic evaluation of advanced esophageal squamous cell carcinoma using gallium-67 SPET : A preliminary study. / Nakahara, Tadaki; Togawa, Takashi; Nagata, Matsuo; Kikuchi, Kazunori; Hatano, Kazuo; Yui, Nobuharu; Kubo, Atsushi.

In: European Journal Of Nuclear Medicine, Vol. 29, No. 8, 2002, p. 1072-1077.

Research output: Contribution to journalArticle

Nakahara, Tadaki ; Togawa, Takashi ; Nagata, Matsuo ; Kikuchi, Kazunori ; Hatano, Kazuo ; Yui, Nobuharu ; Kubo, Atsushi. / Detection and chemoradiotherapeutic evaluation of advanced esophageal squamous cell carcinoma using gallium-67 SPET : A preliminary study. In: European Journal Of Nuclear Medicine. 2002 ; Vol. 29, No. 8. pp. 1072-1077.
@article{3ac12e1be5f446f5bea5a56d6641cd2f,
title = "Detection and chemoradiotherapeutic evaluation of advanced esophageal squamous cell carcinoma using gallium-67 SPET: A preliminary study",
abstract = "About 20 years ago, gallium-67 planar scintigraphy was introduced for the evaluation of advanced esophageal squamous cell carcinoma (AESCC). Although single-photon emission tomography (SPET) is now available in many institutions, there have been no reports regarding the evaluation of AESCC using 67Ga SPET. The aims of this preliminary study were to assess the potential of 67Ga SPET for the detection of AESCC and to further evaluate whether 67Ga SPET can predict the effect of preoperative chemoradiotherapy on AESCC. Thirty-eight patients with histologically proven AESCC (35 men and 3 women, mean age 62±6.9 years) underwent 67Ga SPET before and after preoperative chemoradiotherapy. The histological response to the chemoradiotherapy was determined from a surgical specimen of the esophagus: grade 0, 100{\%} viable tumor cells; grade 1a, 99{\%}-67{\%}; grade 1b, 66{\%}-34{\%}; grade 2, 33{\%}-1{\%}; grade 3, no viable cells. Thirty-seven out of 38 AESCCs (97.4{\%}) were detected on pre-chemoradiotherapy SPET. In these 37 cancers, the tumor-to-lung ratio (TLRpre) was 3.5±2 (range 1.5-9.6). Post-chemoradiotherapy SPET exhibited positive results in 22 cancers, with a TLRpost of 1.8±0.4 (range 1.1-2.6). No patient exhibiting a pathologically complete response had a positive post-chemoradiotherapy SPET result, whereas 80{\%} of patients with negative post-chemoradiotherapy SPET (12/15) results had residual tumor. The percent reduction rate was defined as (TLRpre-TLRpost)/TLRpre x100 and did not correlate with histological response grade (P=0.5169 for Kruskal-Wallis test). These results suggest that 67Ga SPET is a powerful tool for the detection of AESCC. However, 67Ga SPET seems to be of little use in predicting the effects of preoperative chemoradiotherapy on AESCC. Further studies are warranted in order to further clarify the clinical usefulness of 67Ga SPET in patients with AESCC.",
keywords = "Esophageal cancer, Gallium-67, Preoperative chemoradiotherapy, Single-photon emission tomography, Therapeutic effect",
author = "Tadaki Nakahara and Takashi Togawa and Matsuo Nagata and Kazunori Kikuchi and Kazuo Hatano and Nobuharu Yui and Atsushi Kubo",
year = "2002",
doi = "10.1007/s00259-002-0836-z",
language = "English",
volume = "29",
pages = "1072--1077",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Detection and chemoradiotherapeutic evaluation of advanced esophageal squamous cell carcinoma using gallium-67 SPET

T2 - A preliminary study

AU - Nakahara, Tadaki

AU - Togawa, Takashi

AU - Nagata, Matsuo

AU - Kikuchi, Kazunori

AU - Hatano, Kazuo

AU - Yui, Nobuharu

AU - Kubo, Atsushi

PY - 2002

Y1 - 2002

N2 - About 20 years ago, gallium-67 planar scintigraphy was introduced for the evaluation of advanced esophageal squamous cell carcinoma (AESCC). Although single-photon emission tomography (SPET) is now available in many institutions, there have been no reports regarding the evaluation of AESCC using 67Ga SPET. The aims of this preliminary study were to assess the potential of 67Ga SPET for the detection of AESCC and to further evaluate whether 67Ga SPET can predict the effect of preoperative chemoradiotherapy on AESCC. Thirty-eight patients with histologically proven AESCC (35 men and 3 women, mean age 62±6.9 years) underwent 67Ga SPET before and after preoperative chemoradiotherapy. The histological response to the chemoradiotherapy was determined from a surgical specimen of the esophagus: grade 0, 100% viable tumor cells; grade 1a, 99%-67%; grade 1b, 66%-34%; grade 2, 33%-1%; grade 3, no viable cells. Thirty-seven out of 38 AESCCs (97.4%) were detected on pre-chemoradiotherapy SPET. In these 37 cancers, the tumor-to-lung ratio (TLRpre) was 3.5±2 (range 1.5-9.6). Post-chemoradiotherapy SPET exhibited positive results in 22 cancers, with a TLRpost of 1.8±0.4 (range 1.1-2.6). No patient exhibiting a pathologically complete response had a positive post-chemoradiotherapy SPET result, whereas 80% of patients with negative post-chemoradiotherapy SPET (12/15) results had residual tumor. The percent reduction rate was defined as (TLRpre-TLRpost)/TLRpre x100 and did not correlate with histological response grade (P=0.5169 for Kruskal-Wallis test). These results suggest that 67Ga SPET is a powerful tool for the detection of AESCC. However, 67Ga SPET seems to be of little use in predicting the effects of preoperative chemoradiotherapy on AESCC. Further studies are warranted in order to further clarify the clinical usefulness of 67Ga SPET in patients with AESCC.

AB - About 20 years ago, gallium-67 planar scintigraphy was introduced for the evaluation of advanced esophageal squamous cell carcinoma (AESCC). Although single-photon emission tomography (SPET) is now available in many institutions, there have been no reports regarding the evaluation of AESCC using 67Ga SPET. The aims of this preliminary study were to assess the potential of 67Ga SPET for the detection of AESCC and to further evaluate whether 67Ga SPET can predict the effect of preoperative chemoradiotherapy on AESCC. Thirty-eight patients with histologically proven AESCC (35 men and 3 women, mean age 62±6.9 years) underwent 67Ga SPET before and after preoperative chemoradiotherapy. The histological response to the chemoradiotherapy was determined from a surgical specimen of the esophagus: grade 0, 100% viable tumor cells; grade 1a, 99%-67%; grade 1b, 66%-34%; grade 2, 33%-1%; grade 3, no viable cells. Thirty-seven out of 38 AESCCs (97.4%) were detected on pre-chemoradiotherapy SPET. In these 37 cancers, the tumor-to-lung ratio (TLRpre) was 3.5±2 (range 1.5-9.6). Post-chemoradiotherapy SPET exhibited positive results in 22 cancers, with a TLRpost of 1.8±0.4 (range 1.1-2.6). No patient exhibiting a pathologically complete response had a positive post-chemoradiotherapy SPET result, whereas 80% of patients with negative post-chemoradiotherapy SPET (12/15) results had residual tumor. The percent reduction rate was defined as (TLRpre-TLRpost)/TLRpre x100 and did not correlate with histological response grade (P=0.5169 for Kruskal-Wallis test). These results suggest that 67Ga SPET is a powerful tool for the detection of AESCC. However, 67Ga SPET seems to be of little use in predicting the effects of preoperative chemoradiotherapy on AESCC. Further studies are warranted in order to further clarify the clinical usefulness of 67Ga SPET in patients with AESCC.

KW - Esophageal cancer

KW - Gallium-67

KW - Preoperative chemoradiotherapy

KW - Single-photon emission tomography

KW - Therapeutic effect

UR - http://www.scopus.com/inward/record.url?scp=0036325157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036325157&partnerID=8YFLogxK

U2 - 10.1007/s00259-002-0836-z

DO - 10.1007/s00259-002-0836-z

M3 - Article

C2 - 12173022

AN - SCOPUS:0036325157

VL - 29

SP - 1072

EP - 1077

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 8

ER -